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Abstract
Background:Solid pseudopapillary neoplasms (SPNs) of the pancreas are rare tumors considered to be benign although 10% to
15% of SPNs have been reported to be aggressive. Due to its rarity, there have only been a few cases reported regarding the clinical
course of patients with aggressive SPNs. The goal of this study is to describe the clinical course of patients diagnosedwith aggressive
SPNs.
Methods:A PubMed search was done looking for articles describing the clinical course of patients diagnosed with SPN that locally
invaded, recurred, or metastasized. Institutional experience was also added to the pooled data. Patient information was extracted
from the articles. Survival and recurrence curves were plotted and factors associated with survival and recurrences were analyzed.
Results: A total of 59 patients were identiﬁed to have aggressive SPN. Seven patients were males and 52 were females and the
mean age was 37.44±2.21 years. Systemic metastasis constituted 81.4% while recurrence and deep tissue invasion were found in
11.9% and 6.8% of the patients, respectively. Disease-free survival was 45±6.28 months and disease-speciﬁc survival was 152.67
±12.8 months. In survival analysis, age, gender, tumor size, tumor location, combined resection, type of recurrence, and stage IV on
diagnosis were not signiﬁcant factors in predicting survival. However, an unresectable tumor (hazards ratio [HR]=4.871, 95%
conﬁdence interval [CI] 1.480–16.03, P= .009), and metastasis within 36 months (HR=6.399, 95% CI: 1.390–29.452, P= .017)
were identiﬁed as independent variables in predicting survival.
Conclusion: SPNs of the pancreas carry a favorable course. Despite having aggressive properties, patients can still survive for
more than 10 years as long as the tumor can be resected completely.
Abbreviations: CT = computed tomography, HIPEC = hyperthermic intraperitoneal chemotherapy, HR = hazards ratio, PET =
positron-emission tomography, SPN = solid pseudopapillary neoplasm.
Keywords: aggressive pancreas neoplasm, pancreas neoplasm, solid pseudopapillary neoplasm[5–9]1. Introduction
Pancreatic solid pseudopapillary neoplasm (SPN), also referred to
as Frantz tumor, is considered a rare tumor type representing 1%
to 2% of all pancreatic tumors.[1–3] The tumor grows to be
approximately 8–10cm in diameter[4] and is usually identiﬁedEditor: Okasha Hussein.
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1using computed tomography (CT). SPN usually affects young
women between their 3rd and 4th decade of life and is associated
with a good prognosis for patients, with a 5-year survival rate of
up to 97%.[3,10–12]
Pancreatic SPNs are often considered to be benign conditions,
but up to 10% to 15% of cases are reportedly aggressive.[13]
Some SPNs are found to be locally aggressive and invade adjacent
tissues,[14–17] while others are malignant and metastasize to the
liver and peritoneum[1,13,18–20] or to more distant organs such as
the lungs.[21] However, despite their malignant potential, curative
R0, and en bloc resections have been testiﬁed to improve the
overall survival and disease-free survival.[15,22–25] On the
contrary, studies involving other pancreatic tumor types have
shown that metastatic pancreatic cancers only carry a 5-year
overall survival rate of 2%.[26–28]
However, clinical cases of aggressive SPNs are so rare that it is
difﬁcult to generalize and elucidate the natural course of aggressive
SPN in clinical circumstances, thereby making it challenging for
clinicians or surgeons to provide information to patients and their
families regarding the prognosis of aggressive pancreatic SPNs.
In this review, we summarize and describe the long-term
survival outcomes of patients with aggressive SPNs that have
metastasized, recurred, or invaded adjacent organs, as well as
determine the factors contributing to a decrease in the overall
survival rate.
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2.1. Data collection
The PubMed database was searched using the search terms
“aggressive,” “metastatic,” “recurrence,” “deep tissue invasion,”
“peritoneal seeding,”“pseudopapillary,” and“pancreas.”Relevant
articles in the English literature were reviewed, and references were
cross-checked up to the 1st degree, in search of patients that have
pathologically conﬁrmed SPN exhibiting aggressive behavior (i.e.,
metastasis, recurrence, and deep tissue invasion). Patient data, such
as age, sex, tumor size, tumor location, surgery, survival, recurrence,
and time to recurrence, were extracted from those articles.
Researches that grouped their patient characteristics as means
had to be excluded from the study as they had heterogeneous
endpoints. Local patients were also added to the data set. The
complete list of journals from which articles were reviewed can be
found in Appendix 1, http://links.lww.com/MD/C669, whereas
Figure 1 demonstrates the data collection ﬂowchart. The institu-
tional review board of Severance Hospital has approved this study.
2.2. Statistical analysis
The data collected were encoded into the statistical analysis
software, SPSS v23.0. Continuous variables were expressed as
mean± standard deviation and categorical variables were
expressed as frequency (percentage). Journals that had incom-
plete information were plotted as having missing variables. A
Kaplan–Meier survival plot analysis was employed to determine
overall survival, disease-free survival, and recurrence rate. A log-
rank test was used to determine the signiﬁcance of each parameter
with regard to survival and recurrence. Characteristics that
demonstrated a univariate association with survival at a
signiﬁcance level of P< .05 were entered as covariates into a
multivariate proportional hazards regression model. All P-values
<.05 were considered statistically signiﬁcant.
3. Results
3.1. Search results and general characteristics of the
patients with aggressive SPN
A systematic review of literature was performed to search for
relevant articles. A total of 833 potential journals were identiﬁed.Figure 1. Flowchart of data collection.
2Seventeen journals that were not in English were excluded from
the analysis. The remaining 816 journals were cross referenced
and we were able to review 18,485 articles, of which, those that
contained duplicate data sets, and did not contain patient details
were also excluded from the analysis (Fig. 1). After the exclusion
criteria were applied, we were able to collect 51 patients with
aggressive SPN out of 462 (11.0%) total patients described with
SPN from 31 journals (Table 1) and we added 8 more patients
from our local data (Table 2).
A total of 59 patients were included in the study. The number
of women included in this meta-analysis was >7 times compared
with the number of men (female to male ratio of 7.43:1). The
mean age of the patients was 37.44 years. Themost common type
of aggressiveness observed was systemic metastasis, which
constituted 81.4% of the adverse events. Local recurrence and
deep tissue invasion were diagnosed in 11.9% and 6.8% of the
patients, respectively. The rate of curative resection was 91.5%,
whereas the tumor was deemed unresectable in 8.5% of the
patients, and thus, only a biopsy was performed (Table 3).3.2. Survival analysis of aggressive SPN of the pancreas
Disease-free survival was noted to be 45±6.28 months (95%
conﬁdence interval), and 5-year disease-free survival rate was
26.8% (Fig. 2A). Disease-speciﬁc survival for patients with
aggressive SPNs was 152.67±12.8 months (approximately 13
years) and the 5- and 10-year survival rates were 71.1% and
65.5%, respectively (Fig. 2A).
3.3. Factors affecting recurrence of aggressive SPNs
Among the factors measured, only tumors that were determined
to be unresectable on initial evaluation were noted to have a
signiﬁcant effect (P= .008) on recurrence. For these patients,
because the primary tumor was not removed, recurrence
exclusively referred to the development of systemic metastasis.
Using Cox regression survival analysis on these factors, it was
identiﬁed that only unresectable SPNs was a signiﬁcant factor in
determining recurrence (HR=6.019, 95% CI: 1.636–22.149,
P= .007) (Table 4).3.4. Prognostic factors affecting survival in aggressive
SPN
It was noted that other factors were not signiﬁcant in predicting
survival, such as age, sex, tumor size, tumor location, combined
resection (en bloc resection and/or metastasectomy), type of
recurrence, and presence of metastasis on initial diagnosis
(P< .05). However, unresectable tumors (P< .001) and tumors
that metastasize/recur within 3 years (P= .002) had a statistically
negative impact on survival. Using Cox regression survival
analysis, it was analyzed that both unresectability (HR=4.871,
95% CI: 1.480–16.03, P= .009) and recurrence within 36
months (HR=6.399, 95% CI: 1.390–29.452, P= .017) are
independent variables for determining survival period (Table 5).4. Discussion
The natural course of SPNs remains to be an enigma. Due to the
rarity of these tumors, only a few case reports and isolated
institutional experiences describing aggressive SPNs have been
published. Most of the selected journal articles were about the
successful management of aggressive SPNs with various
Table 1
Summary of journals reviewed.
Author, y Number of patients
Aggressive pattern
DeathDeep tissue invasion Liver metastasis Peritoneal metastasis Tumor recurrence
Watanabe (2017) 1 1 1
Park (2006) 1 1 1
Sperti (2008) 1 1
Reindl (2014) 1 1 1
Tang (2005) 2 2 2
Kim (2016) 3 2 1
Chen (2005) 1 1
Lizska (2014 1 1
Alexandrescu (2005) 1 1 1
Tajima (2015) 1 1
Xu (2017) 3 3 1
Serrano (2014) 3 3 1
Lin (2010) 2 2 2
Estrella (2014) 10 4 2 5 2
Takahashi (2005) 1 1
Kang (2014) 1 1 1
Kang (2006) 1 1
Lestelle (2015) 1 1
Yagmur (2015) 1 1
Dixon (2013) 1 1
Nagri (2007) 1 1
Dovigo (2011) 1 1
Sumida (2007) 1 1
Ji (2012) 1 1
Honore (2012) 1 1
Wang (2014) 4 4 2
Gomez (2012) 1 1
Hassan (2005) 1 1
Gedaly (2006) 1 1
Hofmann (2014) 1 1
Ła˛giewska (2012) 1 1
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therapeutic agents,[16,24,29] synchronous surgical excision of
metastasis,[30,31] liver transplantation,[32–34] and even HIPEC.[35]
This can create a form of selection bias in terms of reporting only
successful outcomes. In addition, current staging systems
investigate pathologic characteristics of the excised tumor which
has an inconsistent correlation with the clinical course of the
disease.[30] For example, Kim et al claim that the presence of
angioinvasion, perineural invasion, and nuclear pleomorphism,
pathologic features that are usually associated with malignant
behavior, were not shown to be associated with aggressive
SPN.[15] Watanabe et al and Reindl et al report that high
proliferative index, as in Ki-67, is associated with aggressive
course,[1,36] whereas Tang et al did not ﬁnd a signiﬁcant
association between Ki-67 and aggressive SPN.[19]Table 2
Summary of local patients.
No. Age Sex Tumor location Operation Type of ag
1 46 F Proximal PPPD Peritoneal m
2 81 F Distal Distal pancreatectomy Liver metas
3 45 F Distal Biopsy Liver metas
4 67 M Distal Distal pancreatectomy Liver metas
5 12 F Distal Distal pancreatectomy Liver metas
6 68 F Proximal PPPD Deep soft t
7 46 F Distal Distal pancreatectomy Peritoneal m
8 27 M Proximal PPPD Deep soft t
PPPD, pylorus-preserving pancreaticoduodenectomy.
3The aim of this study was to get a better picture of the natural
course of SPNs through compiling and analyzing published
journal articles in the hope of increasing the number of
comparable cases. To the best of our knowledge, this is the
only report, to date, to have the largest pool of patients with
aggressive SPNs. To overcome the inconsistent correlation
between pathology and natural disease course, we focused on
the clinical outcomes as the endpoint for determining aggres-
siveness.
Our meta-analysis reveals that despite having a 69.5%
recurrence and metastasis rate, SPN still has a favorable survival
period of 152.67±12.8 months (approximately 13 years), with
5- and 10-year survival rates of 71.1% and 65.5%, respectively.
We recognize that both unresectability and recurrence within 3
years are independent factors for decreasing the survival ofgressive behavior Time to recur, mo Follow-up time, mo Status
etastasis 41 58 Alive
tasis 5 21 Died
tasis 2 9 Died
tasis 43 70 Alive
tasis 10 115 Died
issue invasion N/A 0 Died
etastasis 37 53 Died
issue invasion N/A 1 Alive
Table 3
General characteristics.
Total number of study patients: N=59 N (%), mean±standard deviation
Age, y 37.44±2.21
Sex
Male 7 (11.9%)
Female 52 (88.1%)
Tumor size 9.75±4.77
Tumor location
Proximal/distal 18 (30.5%)/41 (69.5%)
Surgery
PPPD/distal pancreatectomy 16 (27.1%)/38 (64.4%)
Unresectable 5 (8.5%)
Aggressiveness
Presence of metastasis on initial diagnosis 17 (28.8%)
Deep tissue invasion 4 (6.8%)
Local recurrence 7 (11.9%)
Systemic metastasis after surgery 48 (81.4%)
Liver: 41 (69.5%),
multiple/carcinomatosis: 7 (11.9%)
Death 17 (28.8%)
PPPD, pylorus-preserving pancreaticoduodenectomy.
Hao et al. Medicine (2018) 97:49 Medicinepatients with aggressive SPNs. We also note that unresectability
and, to some degree, having metastasis on initial diagnosis, are
factors that can lead to recurrence. Kang et al report similar
ﬁndings in their previous multicenter analysis of 351 patients
where having metastasis on diagnosis was signiﬁcant prognostic
factor for tumor recurrence.[37] Another study by Xu et al report
that synchronous metastasis was also a signiﬁcant predictor for
recurrence.[17]
Our study is limited by the number of cases reported as well the
heterogeneity of the published data. As previously mentioned,
most of the information was collected from case reports, owing to
which only basic information was found to be common among
the published articles. Thus we were unable to analyze the effectFigure 2. (A) Survival plot for patients with aggressive solid pseudopapillary
4of certain factors that have been thought to be associated with a
more aggressive SPN. One of these is the Ki-67 index, a
pathologic marker for proliferation. It is believed that an elevated
Ki-67 index identiﬁes a tumor that is more actively thriving and
thus pertains to a more malignant tumor. Several studies have
been made linking elevated Ki-67 with poorer disease-free and
disease-speciﬁc survival.[1,38] Reindl et al reported that increased
proliferative index, together with extensive necrosis and nuclear
atypia, were uncommon pathologic ﬁndings in their patient
leading to decreased survival,[36] whereas Kim et al noted the
association of elevated Ki-67 with the development of distant
metastasis.[39]
Aside from Ki-67 index, the preoperative positron emission
tomography (PET)-CT image has also been identiﬁed as a
potential predictor for aggressive pattern behavior for SPN. Park
et al published their ﬁndings that a Ki-67 ≥ 3% was associated
with increased maximum standard uptake value (SUVmax) on
PET-CT.[40] This ﬁnding coincides with the research done by Kim
et al, where they noted that the SUVmax was signiﬁcantly higher
in patients with T2 and T3 SPN compared with those with T1
tumors.[41]
Information derived from pathologic reports can usually give
us a clue regarding the potentially aggressive behavior of most
tumors. But in the case of SPNs, there has been some debate
regarding the correlation of pathological aggressive character-
istics with clinical aggressive behavior.Watanabe et al report that
the presence of lymphovascular and capsular invasion, duct and
vascular infarction, and tumor necrosis are associated with
aggressive behavior of SPN.[1] A Chinese publication by Xu et al
also reports that lymphovascular invasion and peripancreatic fat
inﬁltration are associated with the development of distant
metastasis.[17] On the contrary, the research of Tang et al claims
that patients with either extrapancreatic extension, vascular or
perineural invasion, or severe cellular pleomorphism did not
demonstratemetastasis during their study period.[19] This claim is
echoed by a study done in Korea on 31 patients with SPN. Kimneoplasm (SPN). (B) Recurrence plot for patients with aggressive SPN.
Table 4
Clinical and pathologic factors affecting recurrence.
N (%) Recurrence (%) Time to recurrence, mo P-value
P-value
Exp (b)
(95% conﬁdence interval)
Age, y .090
<20 10 (16.9%) 5 (50%) 34.8±15.2
20–40 21 (35.6%) 11 (52.4%) 69.6±17.8
>40 28 (47.6%) 25 (89.3%) 36.4±5.2
Sex .934
Male 7 (11.8%) 4 (57.1%) 39.5±18.7
Female 52 (88.2%) 37 (71.1%) 45.7±6.7
Tumor size (diameter), cm
>10 18 (30.5%) 15 (83.3%) .470
>5 41 (80.4%) 26 (63.4%) .436
>2.5 48 (94.1%) 31 (64.6%) .831
Combined resection 14 (23.7%) 7 (50.0%) .610
Tumor location .430
Proximal 18 (30.5%) 11 (61.1%) 38.8±7.00
Distal 41 (69.5%) 30 (73.2%) 47.4±8.22
Aggressiveness .150
Systemic 48 (81.4%) 16 (33.3%) 142.0±15.0
Local 11 (18.6%) 1 (9.1%) 163.6±15.6
Presence of metastasis on initial diagnosis .095
Yes 17 (28.8%) 4 (23.5%) 21.8±12.87 .058
2.858 (0.966–8.454)
No 42 (71.2%) 37 (88.1%) 47.6±6.73
Surgery .008
Complete resection 54 (91.5%) 38 (70.4%) 47.9±6.6
Unresectable 5 (8.5%) 3 (60%) 10.3±4.18 .007
6.019 (1.636–22.149)
Table 5
Clinical and pathologic factors affecting long-term course.
N (%) Death (%)
Mean survival
(months)±standard deviation P-value
P-value
Exp (b)
(95% conﬁdence interval)
Age, y .386
<20 10 (16.9%) 2 (20%) 117.2±12.3
20–40 21 (35.6%) 5 (23.8%) 157.5±22.2
>40 28 (47.6%) 10 (35.7%) 119.7±14.8
Sex .296
Male 7 (11.8%) 3 (42.9%) 97.7±33.7
Female 52 (88.2%) 14 (26.9%) 156.5±13.5
Tumor size (diameter), cm
>10 18 (30.5%) 6 (33.3%) .645
>5 41 (80.4%) 13 (31.7%) .413
>2.5 48 (94.1%) 14 (29.2%) .881
Combined resection 14 (23.7%) 5 (35.7%) .133
Tumor location .429
Proximal 18 (30.5%) 6 (33.3%) 108.9±18.8
Distal 41 (69.5%) 11 (26.8%) 158.1±14.8
Aggressiveness .150
Systemic 48 (81.4%) 16 (33.3%) 142.0±15.0
Local 11 (18.6%) 1 (9.1%) 163.6±15.6
Presence of metastasis on initial diagnosis 17 (28.8%) 5 (29.4%) .571
Recurrence time, mo
∗
.002
Recurrence within 36 months 19 (46.3%) 11 (57.9%) 69.87±13.89 .017
6.399 (1.390–29.452)
Recurrence after 36 mo 22 (53.6%) 2 (9.1%) 200.4±10.47
Surgery
∗
<.001
Complete resection 54 (91.5%) 13 (24.1%) 163.0±12.66
Unresectable 5 (8.5%) 4 (80%) 12.8±4.99 .009
4.871 (1.480–16.03)
∗
Independent factors for survival determined using Cox regression analysis.
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[13] Kang CM, Kim KS, Choi JS, et al. Solid pseudopapillary tumor of the
Hao et al. Medicine (2018) 97:49 Medicineet al report that angioinvasion, perineural invasion, and
moderate nuclear pleomorphism were all not signiﬁcantly
correlated with clinically conﬁrmed malignant behavior. More-
over, the absence of these pathological ﬁndings could not exclude
aggressive behavior.[15]
The SPNs have a unique natural course, and we recommend
further study into the possible causes for the aggressive behavior
of SPNs. As mentioned, perioperative information such as Ki-67
index,[1,36] PET-CT scan quantitative reports,[18] and pathologic
reports[1] have all been suggested to predict SPN behavior. These
information can then be channeled for standardizing the
reporting of other cases of aggressive SPNs to obtain clearer
insights on this disease. Furthermore, we recommend that a
surveillance program should be crafted for each patient, taking
into account the possibility of delayedmetastasis and the negative
impact of early metastasis to overall survival outcomes.Author contributions
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